Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2022 | $5.00 | Overweight | Cantor Fitzgerald |
HIGH POINT, N.C., July 25, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced entry into agreements that include a $10 million investment by CinPax, LLC ("CinPax"), a subsidiary of CinRx Pharma, LLC ("CinRx"). Under the terms of the agreements, CinPax acquired 4,154,549 shares of Class A Common Stock of vTv at an issue price of approximately $2.41 per share, with $6 million paid in cash at closing, and the remaining amount of $4 million payable on November 22, 2022. The agreements also provide for the issuance of 1.2 million warrants to CinRx to acquire additional shares of Class A Common Stock that become exercisable upon agreed vesting triggers (including FDA ap
4 - vTv Therapeutics Inc. (0001641489) (Issuer)
4 - vTv Therapeutics Inc. (0001641489) (Issuer)
4 - vTv Therapeutics Inc. (0001641489) (Issuer)
Cantor Fitzgerald initiated coverage of vTv Therapeutics with a rating of Overweight and set a new price target of $5.00
SC 13G - vTv Therapeutics Inc. (0001641489) (Subject)
SC 13D/A - vTv Therapeutics Inc. (0001641489) (Subject)
SC 13D - vTv Therapeutics Inc. (0001641489) (Subject)
4 - vTv Therapeutics Inc. (0001641489) (Issuer)
HIGH POINT, N.C., Nov. 09, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the third quarter ended September 30, 2023 and provided an update on recent corporate developments. "Our newly appointed Chief Medical Officer, Dr. Thomas Strack, who has been working with us on a consulting basis for several months, is now leading our work on the cadisegliatin Phase 3 program with the goal of initiating studies as soon as possible," said Paul Sekhri, Chief Executive Offi
HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced the appointment of Thomas Strack, M.D. as Chief Medical Officer, effective immediately. "I am pleased to welcome Dr. Strack to the vTv team," said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. "He brings extensive drug development and clinical expertise, as well as a wealth of knowledge in endocrine, metabolic, and cardiovascular diseases. We believe his expertise will be invaluable as
HIGH POINT, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D), today announced the appointment of Elizabeth (Betzy) Keiley as Executive Vice President and General Counsel, effective immediately. "We welcome Betzy to vTv. Her years of legal expertise and deep experience in life sciences will be valuable to the vTv team," said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. "Her decades of experience in both private practice and corporate settings make her an ideal fit for this position. I am confident that we wi
10-Q - vTv Therapeutics Inc. (0001641489) (Filer)
8-K - vTv Therapeutics Inc. (0001641489) (Filer)
8-K - vTv Therapeutics Inc. (0001641489) (Filer)
HIGH POINT, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a clinical stage biopharmaceutical company with a portfolio of novel small molecules and a lead program in diabetes, today reported financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate developments. "Our cadisegliatin program continues to show promise as a new oral adjunct therapy being investigated for improvement in glycemic control and reduction of hypoglycemia in patients with type 1 diabetes. During the quarter, our team made progress addressing the basis for the clinical hold placed on our clinical program by the Food and Drug Adm
Screened first patient in cadisegliatin pivotal trial for type 1 diabetes (T1D); working to resolve clinical hold Expanded Newsoara Biopharma license agreement for PDE4 inhibitor HPP737 to a global license effective upon payment of the $20 million upfront fee HIGH POINT, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today reported financial results for the second quarter ended June 30, 2024, and provided an update on recent corporate developments. "Our small molecule portfolio continues to make significant progress across our
HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial in type 1 diabetes. Cadisegliatin is an oral, liver selective, glucokinase activator that has been well-tolerated in over 500 subjects to date with up to six months of treatment. The clinical hold was based on the discovery of a chromatographic signal in a recent human absorption, distribution,
Cadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1D Cadisegliatin has been dosed in over 500 subjects to date, including 300 patients with diabetes
Gainers Longeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. vTv Therapeutics (NASDAQ:VTVT) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million. Avidity Biosciences (NASDAQ:RNA) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion. Cyclerion Therapeutics (NASDAQ:CYCN) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million. Telesis Bio (NASDAQ:TBIO) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million. Autonomix Medical (NASDAQ:AMIX) stock rose 20.94%
Cantex Pharmaceuticals, Inc., a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Cantex' azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer. This new azeliragon orphan drug designation adds to azeliragon's previous orphan drug designation for the treatment of glioblastoma, received in early 2023.